Rezolve AI has spent the past week unwinding the extreme stress that defined late June — short interest is falling fast, availability has loosened sharply, and borrow costs have pulled back from their 200%-plus peak — yet the underlying setup remains charged enough to keep the July 30 earnings date front of mind.
The most significant shift since the previous notes is the scale of short covering. Short interest has dropped roughly 24% over the past month, falling from a peak near 50 million shares in late May to 38.2 million shares, now equivalent to 12.7% of free float. That retreat accelerated this week: shorts shed more than 7 million shares between June 29 and July 3, a week-on-week decline of nearly 24%. The direction is clearly away from the crowded positioning of early June, when the ORTEX short score peaked above 84 and availability nearly vanished entirely — hitting just 0.07% on June 12, meaning virtually every share in the lending pool was already out on loan. Today's availability reading of 51% is a dramatic recovery from that nadir, though it remains well below the 200%-plus range that would signal a genuinely loose borrow market. The short score has eased to 83.0, still elevated but on a downward trajectory for the past two weeks.
Borrow costs tell a more nuanced story. The cost to borrow has retreated from the 200%-plus record set on June 30 and now runs near 89% APR — painful, but roughly half the peak level. The trajectory of the past five weeks is striking: from 13% in late May, costs multiplied fourteen-fold into the squeeze, and have now partially unwound. At 89%, maintaining a short position still costs roughly $2,500 per year on every $100,000 of exposure. That is not a level where new shorts enter casually, and it helps explain why covering has accelerated even as the stock has given back some of the June 30 gains. The stock closed at $2.84 on July 2, down 7.8% on the day but still up nearly 13% on the week — a volatile range that reflects the competing pressures of ongoing short covering and a stock that has already repriced sharply higher off its post-earnings low.
Options positioning is calm by comparison, and the contrast is worth naming explicitly. The put/call ratio of 0.28 sits just marginally above its 20-day average of 0.27 and barely half a standard deviation from the mean — there is no unusual defensive hedging visible in the options market. The 52-week range for the PCR runs from 0.11 to 0.29, putting the current reading near the top of the historical band, but the z-score of 0.64 rules out any meaningful signal. Options traders are not treating the July 30 earnings date as a tail-risk event, at least not yet.
Insider activity provides a constructive underpinning that has not changed. Founder and CEO Daniel Wagner added shares twice on April 2 at $4.00, committing just over $3.25 million in aggregate. A director bought a further 95,600 shares in mid-May at $2.78. Combined, insiders have been net buyers of roughly 908,000 shares over the past 90 days — and notably, those purchases were made at prices above the current $2.84 close, which means Wagner's open-market buys are currently underwater. BlackRock has added to its position, reporting 11.96 million shares at end of April including a 2 million-share increase, while State Street and Geode have both grown smaller stakes more recently.
The structure heading into July 30 has changed materially from a month ago — the most extreme squeeze mechanics have unwound, borrow has loosened from paralysis to merely expensive, and covering has meaningfully reduced the short overhang. What remains is a stock still carrying 12.7% short interest, an 89% borrow cost that makes rebuilding positions costly, an ORTEX short score still near 83, and a founder who is offside on his own open-market purchases. Whether the Q2 print — the first earnings event since the $300M buyback approval — provides enough new fundamental information to resolve that tension in either direction is the question the July 30 date will answer.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
